Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 3CO3.2Al |
| Molecular Weight | 233.9898 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Al+3].[Al+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O
InChI
InChIKey=PPQREHKVAOVYBT-UHFFFAOYSA-H
InChI=1S/3CH2O3.2Al/c3*2-1(3)4;;/h3*(H2,2,3,4);;/q;;;2*+3/p-6
Potash (Dihydroxyaluminum Sodium Carbonate), a component of
Kompensan-S Forte in Germany, is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. Kompensan-S Forte is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL261 |
|||
Target ID: CHEMBL205 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Kompensan Approved UseGastrointestinal disorders: Dyspepsia, Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Hyperphosphatemia |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of pepsin on the kinetics of HCl neutralization by dihydroxyaluminum sodium carbonate, hydrotalcite and dihydroxyaluminum aminoacetate. | 1991 |
|
| Automation of dihydroxyaluminum sodium carbonate analysis in antacid tablets by energy dispersive X-ray fluorescence. | 1990-05-01 |
|
| Studies of neutralizing properties of antacid preparations. Part 4: Application of Weibull distribution function to neutralization of dihydroxyaluminum sodium carbonate. | 1988-07 |
|
| Exchange of sodium by magnesium in aluminum hydroxycarbonate gel. | 1984-07 |
|
| Studies on antacids. V. The preparation and properties of dihydroxy aluminum sodium carbonate. | 1955-04 |
Patents
Sample Use Guides
Usual Adult Dose for Dyspepsia: 500 to 600 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Duodenal Ulcer: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Erosive Esophagitis: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Gastric Ulcer: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Gastroesophageal Reflux Disease: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Zollinger-Ellison Syndrome: 500 to 3600 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Hyperphosphatemia: 500 to 1000 mg orally 4 times a day, with meals and at bedtime. The dosage should be titrated to the serum phosphate level.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 331.11
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
14455-29-9
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
PRIMARY | |||
|
ALUMINIUM CARBONATE
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
PRIMARY | |||
|
4526
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
PRIMARY | |||
|
210894-13-6
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
SUPERSEDED | |||
|
CHEMBL2109015
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
PRIMARY | |||
|
SUB12815MIG
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
PRIMARY | |||
|
1GA689N629
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
PRIMARY | |||
|
89858
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
PRIMARY | |||
|
53547-27-6
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
SUPERSEDED | |||
|
DTXSID30891680
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
PRIMARY | |||
|
C45678
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
CONCEPT | Industrial Aid | ||
|
1GA689N629
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
PRIMARY | |||
|
100000077670
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
PRIMARY | |||
|
238-440-2
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
PRIMARY | |||
|
C120559
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
PRIMARY | |||
|
C025173
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
PRIMARY | |||
|
10353966
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
PRIMARY | |||
|
18789
Created by
admin on Mon Mar 31 19:26:10 GMT 2025 , Edited by admin on Mon Mar 31 19:26:10 GMT 2025
|
ALTERNATIVE |
SUBSTANCE RECORD
